All In MedTech

Device Trial Radar · NCT07936643

Artificial Intelligence Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda

TEST4TPT: AI Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,804 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,804

Planned (sponsor's estimate)

Start

Apr 2027

Primary completion

Dec 2028

Study completion Apr 30, 2029

Sponsor

Lead sponsor
KNCV Tuberculosis FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute for Medical Research, Tanzania; Fundação Manhiça; Barcelona Institute for Global Health; Makerere University Lung Institute; Mildmay Uganda Limited; London School of Hygiene and Tropical Medicine; Mwitikio wa Kudhibiti Kifua Kikuu na Ukimwi Tanzania
First posted
Nov 13, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 5 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Artificial Intelligence Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda (TEST4TPT) project will evaluate a person-centered approach to improve access to tuberculosis infection (TBI) testing and linkage to tuberculosis preventive treatment (TPT) in Mozambique, Tanzania, and Uganda. The project will generate evidence on the feasibility, acceptability, clinical utility, diagnostic and operational performance, and implementation of a novel point-of-care TBI testing approach, including home- or community-based testing and artificial intelligence (AI)-assisted reading. By bringing testing closer to people at increased risk of tuberculosis (TB), TEST4TPT aims to reduce barriers to care, support timely TPT initiation, and contribute to improved completion of preventive treatment. The overall goal of TEST4TPT is to evaluate an integrated, home-based approach to TBI testing using SIILTIBCY (an authorized diagnostic skin test used to detect TBI), community health worker (CHW)-facilitated support, and AI-assisted result reading, with the aim of improving initiation and completion of TPT among close contacts of people newly diagnosed with pulmonary TB disease.

Conditions

  • Tuberculosis Infection, Latent
  • Tuberculosis Prevention

Interventions

  • Standard-of-care TB contact investigation and TPT assessmentOther

    Facility-based identification and assessment of close contacts of people with pulmonary tuberculosis (TB), with assessment for tuberculosis preventive treatment (TPT) eligibility according to national guidelines. Tuberculosis infection (TBI) testing may or may not be included depending on local availability and practice.

  • Facility-based SIILTIBCY testingDiagnostic test

    Close contacts receive SIILTIBCY testing at the health facility. SIILTIBCY is administered intradermally and the test result is read 48-72 hours after administration at the health facility.

  • Home-based SIILTIBCY testing with SmartPatch/TBConnect AI-assisted reading, conditional on Sub-study 1 resultsDiagnostic test

    Close contacts will receive home-based tuberculosis (TB) infection screening and SIILTIBCY testing delivered by trained community health workers (CHWs), where permitted by national guidelines. CHWs will return to the household 48-72 hours after SIILTIBCY administration to assess the test result. AI-assisted interpretation using the SmartPatch and TBConnect application may be used if supported by the findings of Sub-study 1 and approved for use in the trial. Participants requiring further clinical assessment will be referred or linked to the health facility, and eligible participants will be linked to tuberculosis preventive treatment according to national guidelines.

  • SmartPatch reading using the TBConnect AI-assisted interpretationDevice

    The SmartPatch and AI-driven TBConnect application are used to support AI-assisted interpretation of the SIILTIBCY skin test. The SmartPatch is applied to the participant's forearm and linked to the TBConnect platform through a unique QR code. Images of the SIILTIBCY administration site are captured using TBConnect for AI-assisted interpretation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of eligible contacts initiating tuberculosis preventive treatment per index TB patientTime frame: From sub-study 2 initiation through study completion, approximately 15 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.